AL-LAD

(6aR,9R)-N,N-diethyl-7-prop-2-enyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide

Overview

AL-LAD belongs to Psychedelics / Ergolines.

Key safety note: AL-LAD is a potent psychedelic active at roughly 100 µg: accurate low dosing (ideally volumetric) is essential.[1]
Effects
Subjective effects vary. What a substance feels like depends on dose, individual physiology, mindset, and setting. The points below describe commonly reported effects, not guaranteed, uniform, or desirable outcomes.
  • Broadly LSD-like, but frequently described as more clear-headed and less anxiety-provoking: 'lacking the vaguely sinister push' sometimes attributed to LSD
  • Visuals are bright, colourful and cartoon-like, slow and smooth in motion, with somewhat less visual distortion than an equivalent dose of LSD
  • A stimulating, euphoric body high with tingling. A shorter overall duration than LSD and a long, gentle come-down
Dosing & duration
Harm-reduction note: These are commonly cited reference ranges, not a recommendation or a “safe” dose. Potency, purity, body chemistry, tolerance, and drug combinations vary widely. Start low, go slow, wait for full effects before redosing, and never assume an unknown product matches these figures. Missing data is not evidence of safety.

Oral. Shulgin's TiHKAL account lists an oral range of roughly 80–160 µg. Community harm-reduction sources describe a common range around 100–225 µg. AL-LAD is about equipotent with LSD and active at ~100 µg, so dose it as carefully as LSD: volumetric dosing of a solution is strongly recommended for accuracy.

Dose ranges

Threshold

~20 µg

Light

50–100 µg

Common

100–225 µg

Strong

225–350 µg

Duration

onset

20–60 min

peak

2.5–5 h

total

7–10 h

Chemical & Physical Properties
FormulaC22H27N3O
Molar mass349.5 g/mol
StateNot reported
Melting pointNot reported
Boiling pointNot reported
DensityNot reported
Vapor pressureNot reported
pKaNot reported
LogP3.6 (predicted, XLogP3)
SolubilityNot reported
Refractive indexNot reported
Identifiers & Synonyms
CAS65527-61-9
CAS (enantiomer)
PubChem CID15227511
InChIKeyJCQLEPDZFXGHHQ-OXQOHEQNSA-N
InChIInChI=1S/C22H27N3O/c1-4-10-25-14-16(22(26)24(5-2)6-3)11-18-17-8-7-9-19-21(17)15(13-23-19)12-20(18)25/h4,7-9,11,13,16,20,23H,1,5-6,10,12,14H2,2-3H3/t16-,20-/m1/s1
SMILESCCN(CC)C(=O)[C@H]1CN([C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1)CC=C

Synonyms

  • ALLAD
  • Allyl-LAD
  • 6-Allyl-6-nor-LSD
  • N6-allyl-6-norlysergic acid diethylamide
  • 9,10-Didehydro-6-allyl-N,N-diethylergoline-8β-carboxamide
Pharmacodynamics & Biochemistry

A semi-synthetic lysergamide: the N6-allyl analogue of LSD (6-allyl-6-nor-LSD). Like LSD it acts as a potent full agonist at the serotonin 5-HT2A receptor, the target most closely linked to classic psychedelic effects. Binding work on the N6-substituted norlysergamides reports high 5-HT2/5-HT2A affinity (Kᵢ in the low single-digit-to-~8 nM range). AL-LAD is also described as interacting with other serotonin subtypes (5-HT1, 5-HT2C) and with dopamine D1 and D2 receptors, consistent with LSD's promiscuous lysergamide profile. In animals AL-LAD fully substitutes for LSD in drug-discrimination and produces the 5-HT2A-mediated head-twitch response. It is roughly 3.5× more potent than LSD in rat drug-discrimination yet only slightly less potent than LSD in the mouse head-twitch assay (ED₅₀ 174.9 vs 132.8 nmol/kg), and is reported to be about equipotent with LSD in humans.

Biological targets

  • 5-HT2A
  • D2
  • D1

Binding & functional measurements

TargetMeasurementSpecies
5-HT2A receptorKi 8.1 nMRat
D2 receptorKi 12 nMRat (striatum, [³H]spiperone)
D1 receptorKi 189 nMRat (striatum, [³H]SCH23390)
5-HT1B receptorKi 16 nMRat
Pharmacokinetics
BioavailabilityNot reported
TmaxNot reported
Half-lifeNot established in humans
VdNot reported
Protein bindingNot reported
MetabolismPresumed extensive hepatic metabolism typical of the lysergamides. The in-vitro metabolism of AL-LAD has been characterised analytically, but human pharmacokinetics, including a formal elimination half-life, have not been established. Its overall duration of action (~7–10 h) is somewhat shorter than that of LSD
ExcretionNot reported
Toxicology & Safety
Harm-reduction note: Toxicity and risk depend on dose, route, purity, combinations, setting, and individual health factors. Missing harms should never be interpreted as evidence of safety.

Not reported

AL-LAD is a potent psychedelic active at roughly 100 µg: accurate low dosing (ideally volumetric) is essential. Dedicated human safety and toxicity data are very limited. Risks are inferred from its close structural and pharmacological similarity to LSD. Expect a long experience (about 7–10 hours) with the psychological risks common to strong serotonergic psychedelics: anxiety, confusion, transient blood-pressure and heart-rate increases, and the possibility of precipitating or worsening psychosis in vulnerable people. As with all serotonergic drugs, combining it with other serotonergic agents can add to serotonergic load. Limited data must never be read as evidence of safety.[1]

Legal Status
Legal note: Legal status can change over time and may vary by country, region, formulation, analogue status, prescription context, and enforcement practice. Always confirm with current official sources before relying on this section.
Interactions & Contraindications

Drug interactions

Lithium, Tramadol Markedly raise the risk of seizures and psychosis with serotonergic psychedelics, avoid.
Stimulants (amphetamines, cocaine) Add cardiovascular strain, anxiety and thought loops, and can intensify a challenging experience.
Cannabis Can strongly and unpredictably potentiate the effects and increase anxiety or confusion.
SSRIs, SNRIs, MAOIs Add to serotonergic load. MAOIs in particular may unpredictably alter the response.

Contraindications

Personal or family history of psychosis, schizophrenia or bipolar disorder
Cardiovascular disease, hypertension or arrhythmia significant or uncontrolled disease or hypertension.
Concurrent MAOI, SSRI/SNRI or other serotonergic medication includes concurrent lithium or tramadol (seizure/psychosis risk).
Settings where impairment or dissociation risks injury (driving, water, heights) long (~7-10 h) duration and potency call for a prepared, supported setting.
Usage & Context
  • Research.
  • Recreational.
Sources & Evidence

Further Information